Acorda Resubmits NDA for Parkinson’s Disease Candidate Inbrija

(December 8, 2017) – Acorda Therapeutics announced that it has resubmitted the new drug application for its late stage pipeline candidate, Inbrija, to the Federal Drug Administration. Currently, the company is seeking approval for Inbrija in the United States as a treatment option for symptoms of OFF periods in people with Parkinson’s taking a carbidopa / levodopa regimen. Read more…